Clinical trial NCT04404491 - References

Esophageal Malignant Neoplasm, Local Recurrence — Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence

Citation(s)

•   Chen B, Li Q, Li Q, Qiu B, Xi M, Liu M, Hu Y, Zhu Y
  Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study. Oncologist. 2020 Apr;25(4):308-e625. doi: 10.1634/theoncologist.2019-0931. Epub 2019 Dec 27.
•   Fassan M, Cavallin F, Guzzardo V, Kotsafti A, Scarpa M, Cagol M, Chiarion-Sileni V, Maria Saadeh L, Alfieri R, Castagliuolo I, Rugge M, Castoro C, Scarpa M
  PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. Cancer Med. 2019 Oct;8(13):6036-6048. doi: 10.1002/cam4.2359. Epub 2019 Aug 20.
•   Jingu K, Umezawa R, Yamamoto T, Matsushita H, Ishikawa Y, Kozumi M, Kubozono M, Takahashi N, Kadoya N, Takeda K
  Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer. Jpn J Clin Oncol. 2017 Mar 1;47(3):200-205. doi: 10.1093/jjco/hyw195.
•   Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroglu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T
  KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019 Apr;15(10):1057-1066. doi: 10.2217/fon-2018-0609. Epub 2019 Feb 8.
•   Kelly RJ
  Immunotherapy for Esophageal and Gastric Cancer. Am Soc Clin Oncol Educ Book. 2017;37:292-300. doi: 10.14694/EDBK_175231. Review.
•   Nakajima T, Ogata T, Nomiya T, Nonaka T, Nakayama Y, Kano K, Maezawa Y, Segami K, Ikeda K, Sato T, Cho H, Yoshikawa T
  [Radical Chemoradiotherapy for Recurrent Esophageal Cancer after Curative Esophagectomy]. Gan To Kagaku Ryoho. 2016 Nov;43(12):1564-1566. Japanese.
•   Sato D, Motegi A, Kadota T, Kojima T, Bando H, Shinmura K, Hori K, Yoda Y, Oono Y, Zenda S, Ikematsu H, Akimoto T, Yano T
  Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrence. Esophagus. 2020 Jan 21. doi: 10.1007/s10388-020-00715-y. [Epub ahead of print]
•   Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhlén M, Mardinoglu A, Leandersson K, Jirström K
  Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Front Oncol. 2019 Mar 13;9:136. doi: 10.3389/fonc.2019.00136. eCollection 2019.
•   Yang H, Wang K, Wang T, Li M, Li B, Li S, Yuan L
  The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer. Front Oncol. 2020 Mar 5;10:300. doi: 10.3389/fonc.2020.00300. eCollection 2020. Review.
•   Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu C, Sun NN, Li XJ, Zhai SC, Niu LJ, Zhang JB, Ji HL, Li XM
  A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. PLoS One. 2015 Jun 5;10(6):e0128616. doi: 10.1371/journal.pone.0128616. eCollection 2015.

The Third Phase of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence Was Compared With the Clinical Comparison

Details for clinical trial NCT04404491